An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
about
Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer.Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report.Canertinib induces ototoxicity in three preclinical models.Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.Update on systemic therapy of advanced non-small-cell lung cancer.Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
P2860
Q35151114-0EA65E82-59B8-4FD0-8CF8-AF50D8229D9DQ35434188-3ED9C8F3-52AA-46B5-8F9C-0D161B539043Q35551845-EE2BAD62-043A-4B1A-8392-C9AFE1C49B67Q35786366-05A5C296-5DA0-4154-948D-17A2E8E02F3CQ35803501-83E073A9-A787-4207-B464-B0B28D582ADDQ36088986-DC84FE32-0273-4455-9C4A-DDAFB2765AA5Q36482433-8C3B647E-0802-4737-9C96-CA5E30D164A7Q38237463-6E967F91-7367-41A5-9988-079CB386B258Q38390044-5F3619A9-FC75-4E96-A19A-608A1F3D8A80Q38625550-78A48D43-AC06-430A-8CC0-70BED9F19292Q43801167-DAF16D77-9FA5-4571-AFE7-46B26DE4D05FQ50872393-8E6AE9F1-ED37-45B1-8B90-101972ADE67C
P2860
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
An update on molecularly targe ...... rs and anti-angiogenic agents.
@en
type
label
An update on molecularly targe ...... rs and anti-angiogenic agents.
@en
prefLabel
An update on molecularly targe ...... rs and anti-angiogenic agents.
@en
P2860
P1476
An update on molecularly targe ...... rs and anti-angiogenic agents.
@en
P2093
P2860
P2888
P304
P356
10.1007/S12094-012-0964-2
P577
2013-01-29T00:00:00Z